Site growth

What buyers look for when they acquire a clinical research site

By TrialNotice · Updated
Drone view of a standalone single story medical office building in a leafy suburb at golden hour
Short answerBuyers value clinical research sites on EBITDA, adjusted for scale, backlog of awarded studies, margins, compliance record, therapeutic specialization, location, sponsor diversification, and investigator depth. Proven recruitment performance and patient access matter directly: buyers reward sites that reliably hit enrollment timelines, and patient data assets are increasingly a reason to acquire.
Source note: the valuation factors below come mainly from an investment bank that advises on site sales, so they reflect the buyer and seller market view. This is general information, not financial advice.

What do buyers evaluate?

  1. Financial performance and scale. Revenue, EBITDA, and margins. Larger sites command higher multiples (Objective IBV).
  2. Backlog. Studies awarded but not yet started give buyers visibility into future revenue.
  3. Therapeutic focus. Oncology, CNS, and rare disease capabilities are described as the most strategically valuable.
  4. Location and patient access. Sites in diverse, dense markets value higher because they enroll faster, and a demonstrated ability to meet enrollment timelines raises buyer confidence.
  5. Compliance and quality. GCP adherence, audit history, SOPs, and training. Unresolved FDA findings can materially reduce value.
  6. Technology. CTMS and eSource adoption signal maturity.
  7. Diversification. Revenue concentrated in one sponsor or CRO is a risk, and overreliance on a single principal investigator constrains value (Objective IBV).
  8. Data assets. Curated patient registries and patient data are increasingly treated as acquisition catalysts (Objective IBV).

Why does investigator depth matter so much?

Because investigator turnover is high: in 2020, 66% of principal investigators filed only one Form 1572 (Tufts CSDD). A site whose sponsor relationships, patient sources, and referral network live with one physician is worth less than one where they are documented and shared.

What about the other side of consolidation?

Critics have raised concerns about how private equity consolidation of sites and ethics boards could affect patients and costs (Private Equity Stakeholder Project). Owners weighing a sale should understand both views. See should you sell your research site.

How do you strengthen patient access before a sale?

Make it institutional rather than personal: a documented list of referring practices, referral volume by physician, and a repeatable outreach process. That turns patient access from a claim into an asset a buyer can verify.

Get your study in front of the right local physicians

TrialNotice builds a physician referral pipeline around one active study. We identify relevant local physicians within driving distance of your site, send study aligned direct mail, follow up by email and LinkedIn, track engagement with recipient level QR codes, and route warm responses into your site team's workflow.

Talk to TrialNotice

Sources

  1. Objective Investment Banking and Valuation, "Valuation of Clinical Research Sites: What Buyers Look For"
  2. Private Equity Stakeholder Project, "Private equity moves into clinical trials" (November 2025)
  3. Applied Clinical Trials, "Tracking Change in the Global Investigative Site Landscape" (Tufts CSDD)

Keep reading

Two clinical research site staff members reviewing a growth plan together in a bright office
Site growth

How to grow a clinical research site: a practical playbook

Research sites grow by building a record sponsors can verify: enrollment, startup speed, and screen failure. Here is what the data says about site growth, why sponsors reuse sites, and a six step playbook.

 Research site director presenting enrollment results to sponsor representatives across a conference table
Site growth

How research sites get more studies from sponsors and CROs

Sponsors award more studies to sites that enroll reliably, start fast, and forecast honestly. Here is how sponsors choose, why new sites face a slower path, and what a site can do to win repeat work.

 Sponsor clinical operations team reviewing site maps and performance charts on a large screen
Site growth

How sponsors and CROs select clinical trial sites

Sponsors shortlist sites with historical data and epidemiology, send feasibility questionnaires, then choose on patient access, past enrollment, and startup speed. Here is the process, how it evolved, and what it means for sites.